Efficacy and safety of neoadjuvant chemotherapy combined with dual-targeted treatment in triple-positive breast cancer
Objective To investigate the efficacy and safety of neoadjuvant treatment with paclitaxel,platinum,trastuzumab and pertuzumab in triple-positive breast cancer(TPBC).Methods A retrospective analysis was conducted on the data of 50 TPBC patients who received the neoadjuvant treatment with paclitaxel,platinum,trastuzumab and pertuzumab in Beijing Chaoyang District Sanhuan Cancer Hospital from January 2020 to August 2023.All participants were female,with a median age of 49 years.All patients underwent surgery after 6 cycles of neoadjuvant chemotherapy.Subgroup analyses were performed according to paclitaxel type,patient age,menstrual status,breast tumor diameter,lymph node metastasis,hormone receptor status and Ki-67 expression level.Results The complete response,partial response and stable disease rates were 30.0％(15/50),58.0％(29/50),and 12.0％(6/50)respectively.The objective response rate was 88.0％(44/50),and the disease control rate was 100％.The pathological complete response(pCR)rate was 30.0％(15/50),and non-pCR rate was 70.0％(35/50).Paclitaxel type was not associated with pCR in TPBC patients(P=0.602).Patient age,menstrual status,breast tumor diameter,lymph node metastasis,hormone receptor status,and Ki-67 expression level were not associated with pCR(all P＞0.05).The main adverse reactions were gastrointestinal reactions,myelosuppression,hand and foot numbness and liver insufficiency.Most adverse reactions were Grades 1-2,with few cases of Grades 3-4 being reported.Adverse reactions can be improved after symptomatic treatment.Conclusion The pCR rate of TPBC patients treated with neoadjuvant chemotherapy combined with dual-targeted therapy was 30.0％,and the adverse reactions were tolerable.
Breast neoplasmsTriple positiveNeoadjuvant therapyEfficacySafety
NETL
NSTL
万方数据
